Thus, crossing KCa3.1−/− mice with transgenic breast cancer mouse models provided evidence that the impact KCa3.1 targeting in cancer cells may be further modulated by KCa3.1 targeting in noncancerous cells (Steudel et al., 2017). The gene discussed is KCNN4; the disease is breast cancer.